A detailed history of Westover Capital Advisors, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Westover Capital Advisors, LLC holds 14,452 shares of CPRX stock, worth $314,620. This represents 0.06% of its overall portfolio holdings.

Number of Shares
14,452
Previous 14,470 0.12%
Holding current value
$314,620
Previous $230,000 3.04%
% of portfolio
0.06%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$14.68 - $16.92 $264 - $304
-18 Reduced 0.12%
14,452 $223,000
Q1 2024

May 03, 2024

SELL
$13.18 - $17.11 $923,997 - $1.2 Million
-70,106 Reduced 82.89%
14,470 $230,000
Q4 2023

Feb 06, 2024

SELL
$11.78 - $17.29 $11,096 - $16,287
-942 Reduced 1.1%
84,576 $1.42 Million
Q3 2023

Nov 13, 2023

SELL
$11.69 - $15.02 $203,160 - $261,032
-17,379 Reduced 16.89%
85,518 $999,000
Q2 2023

Aug 11, 2023

BUY
$11.5 - $18.08 $1.18 Million - $1.86 Million
102,897 New
102,897 $1.38 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.24B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Westover Capital Advisors, LLC Portfolio

Follow Westover Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Westover Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Westover Capital Advisors, LLC with notifications on news.